Item 7.01. Regulation FD Disclosure

On August 16, 2022, LENSAR, Inc. (the "Company") issued a press release announcing the first commercial cases performed with the ALLY™ Adaptive Cataract Treatment System ("ALLY" or the "ALLY System"). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated into this Item 7.01 by reference.

The information contained in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.

Item 8.01. Other Events

On August 16, 2022, the Company announced the performance of the first commercial cases with the ALLY System. Dr. Robert Weinstock of The Eye Institute of West Florida performed 15 laser-assisted cataract surgery cases following the recent installation of his ALLY System

Following ALLY's FDA clearance in June 2022, as previously announced, LENSAR has been working closely with select cataract surgeons and surgery centers to integrate the ALLY System. The Company expects to install 8 to 12 ALLY Systems in 2022 as part of a controlled, commercial launch.

Forward-Looking Statements

Statements in this Current Report on Form 8-K regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited, to statements regarding the Company's development and commercialization of ALLY. Forward-looking statements may be identified by words such as "anticipates," "believe," "continue," "expect," "intend," "may," "plan to," "potential," "projects," "will," and other similar words or expressions, or the negative of these words or similar words or expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors, including, without limitation, the risks referred to under the section "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2022, as such factors may be updated from time to time in the Company's other filings with the SEC, which filings are accessible on the SEC's website at www.sec.gov and the Investors & Media page of the Company's website at https://ir.lensar.com. All forward-looking statements speak only as of the date of this Current Report on Form 8-K and, except as required by applicable law, the Company has no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits



Exhibit No.                              Description



99.1          Press Release of LENSAR, Inc., dated August 16, 2022
104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses